tradingkey.logo

Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)

ReutersJan 7, 2026 2:49 PM

- CERo Therapeutics Holdings Inc CERO.PK:

  • CERO THERAPEUTICS PROVIDES CLINICAL UPDATE ON PHASE 1 TRIAL OF CER-1236 IN AML (CERTAINT-1) HIGHLIGHTING KEY SAFETY DATA AND PLATELET TRANSFUSION–FREE INTERVAL OBSERVED IN A PATIENT WITH MYELODYSPLASTIC SYNDROME/AML

  • CERO THERAPEUTICS HOLDINGS INC - NO ADVERSE EVENTS REPORTED IN FIRST COHORT OF CERTAINT-1 TRIAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI